News about "Sun Pharmaceutical Industries "

Sun Pharma Establishes Dermatology Professorship at Mount Sinai

Sun Pharma has established a USD 2.5 million endowed professorship in dermatology at the Icahn School of Medicine at Mount Sinai.

Sun Pharmaceutical Industries | 07/10/2026 | By News Bureau

Sun Pharma Presents Long-Term Leqselvi Data

Sun Pharma presents long-term safety and efficacy data for Leqselvi in adults with severe alopecia areata at the EADV Congress 2026.

Sun Pharmaceutical Industries | 03/10/2026 | By News Bureau

Sun Pharma Subsidiaries Reach Settlement in US Generic Drug Pricing Antitrust Litigation

Sun Pharma subsidiaries have reached a settlement with a plaintiff in a US generic drug pricing antitrust case for a confidential amount.

Sun Pharmaceutical Industries | 15/09/2026 | By News Bureau |  102

Sun Pharma Wins Key US Appeals Court Ruling in Lipitor Antitrust Litigation

Sun Pharma wins a key US appeals court ruling in the Lipitor antitrust case, with summary judgment upheld in favor of the company and its subsidiaries.

Sun Pharmaceutical Industries | 17/08/2026 | By News Bureau |  175

Philogen Resubmits EMA Marketing Application for Melanoma Therapy Nidlegy with Updated Phase 3 Data

Philogen has resubmitted its EMA marketing application for investigational melanoma therapy Nidlegy, supported by updated Phase 3 clinical data demonstrating reduced risk of relapse or death and an extended patient follow-up period.

Sun Pharmaceutical Industries | 28/07/2026 | By News Bureau |  154

Sun Pharma to Acquire Innovcare Lifesciences in INR 271 Crore Strategic Deal

Sun Pharma will acquire Innovcare Lifesciences for INR 271.2 crore, strengthening its presence in pharmaceuticals, nutraceuticals, and cosmeceuticals through the acquisition of the Mumbai-based healthcare company.

Sun Pharmaceutical Industries | 22/06/2026 | By News Bureau |  128

Sun Pharmaceutical Industries Signs Definitive Agreement to Acquire Organon

Sun Pharmaceutical Industries signs a definitive agreement to acquire Organon for USD 14 per share, valuing the deal at USD 11.75B EV. The merger aims to leverage complementary portfolios and global scale for long-term growth.

Sun Pharmaceutical Industries | 27/04/2026 | By News Bureau |  312

US FDA Imports Alert Hits Sun Pharma's Halol Manufacturing Plant After OAI Classification

Sun Pharmaceutical Industries has confirmed that its Halol manufacturing facility in Gujarat, India, has been classified as “Official Action Indicated” (OAI) by the US Food and Drug Administration following a compliance inspection conducted in June 2025.

Sun Pharmaceutical Industries | 11/09/2025 | By Darshana |  1047

Sun Pharma Halol Facility Classified OAI by US FDA, Shipments Restricted

The US Food and Drug Administration (FDA) has classified Sun Pharma's Halol facility as “Official Action Indicated” (OAI) following an inspection conducted between June 2 and June 13, 2025.

Sun Pharmaceutical Industries | 10/09/2025 | By Dineshwori |  966

Sun Pharma's Phase 3 Clinical Trials of ILUMYA in Active Psoriatic Arthritis Achieve Primary Endpoint

Sun Pharmaceutical Industries has reported positive top-line results from two Phase 3 trials (INSPIRE-1 and INSPIRE-2), demonstrating that ILUMYA (tildrakizumab 100 mg) significantly improved symptoms of active psoriatic arthritis over 24 weeks compared to placebo.

Sun Pharmaceutical Industries | 21/07/2025 | By Mrinmoy Dey |  388